Search

everythinglearnresearchcommunity

for

Search:↓

Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.

Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Early balding may be a sign of future prostate problems.

Low dose finasteride causes only small changes in PSA levels in older men with BPH.

Dutasteride works better than finasteride for preventing and treating prostate cancer.

Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.

Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.

Large prostate patients more likely to have hair loss.

Low doses of Coffea arabica seed extract prevent prostate growth and lower uric acid and PSA levels.

Hair loss gene linked to prostate issues.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Dutasteride reduces DHT more effectively than finasteride.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

CT scans can find serious prostate cancer even when PSA levels are low.